Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy

Journal of the American College of Cardiology

Volumn 41, Issue 3, 2003, Pages 420-425

  Anderson, Todd J ^a,b   Hubacek, Jaroslav ^a   George Wyse, D ^a   Knudtson, Merril L ^a  

^a CALGARY HEALTH REGION   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BICARBONATE; CHELATING AGENT; EDETIC ACID; GLYCERYL TRINITRATE; LIDOCAINE; MAGNESIUM SULFATE; MULTIVITAMIN; PLACEBO;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CHELATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ULTRASOUND; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0037419865     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02770-5     Document Type: Article

References (50)

1. Holden C. Alternative medicine: NIH trial to test chelation therapy. Science 2002;297:1109.
2. Quan H, Ghali WA, Verhoef M, Norris CM, Galbraith PD, Knudtson ML. Use of chelation therapy after coronary angiography. Am J Med 2001;111:686-91.
3. Prozema TC. Protocols for chelation therapy. J Adv Med 1997;10:1-100.
4. Cappel LT, Janson M. EDTA chelation therapy in the treatment of vascular disease. J Cardiovasc Nursing 1996;10:78-86.
5. Lamas GA, Ackermann A. Clinical evaluation of chelation therapy: is there any wheat amidst the chaff? Am Heart J 2000;140:4-5.
6. Anderson TJ. Oxidative stress, endothelial function and coronary atherosclerosis. Cardiologia 1997;42:701-14.
7. Benzuly KH, Padgett RC, Kaul S, Piegors DJ, Armstrong ML, Heistad DD. Functional improvement precedes structural regression of atherosclerosis. Circulation 1994;89:1810-8.
8. Hornig B, Drexler H. Reversal of endothelial dysfunction in humans. Coron Artery Dis 2001;12:463-73.
9. Elihu N, Anandasbapathy S, Frishman WH. Chelation therapy in cardiovascular disease: enthylendiaminetetraacetic acid and desferoxamine. J Clin Pharmacol 1998;38:101-5.
10. Knudtson M, Galbraith PD. Chelation therapy for ischemic heart disease. A randomized controled trial. JAMA 2002;287:481-6.
11. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
12. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-41.
13. Sorensen KE, Celermajer DS, Spiegelhalter DJ, et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995;74:247-53.
14. Anderson TJ, Elstein E, Haber HE, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000;35:60-6.
15. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
16. Schnell G, Robertson A, Malley L, Huston D, Anderson TJ. Impaired brachial artery endothelial function is not predicted by elevated triglycerides. J Am Coll Cardiol 1999;33:2038-43.
17. Moncada S, Higgs A. The L-arginine-NO pathway. N Engl J Med 1993;329:2002-12.
18. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis 1997;39:287-324.
19. Anderson TJ. Oxidative stress, endothelial function and coronary atherosclerosis. Cardiologia 1997;42:701-14.
20. Casdorph RH. EDTA chelation therapy: efficacy in atherosclerotic heart disease. J Holistic Med 1981;3:53-9.
21. Clarke NE, Clarke CN, Mosher RE. The "in vivo" dissolution of metastic calcium: an approach to atherosclerosis. Am J Med Sci 1955;229:142-9.
22. Clarke NE, Clarke CN, Mosher RE. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci 1960;232:654-6.
23. Cranton EM, Frackelton JP. Free radical pathology in age associated diseases: treatment with EDTA chelation, nutrition and antioxidants. J Holistic Med 1984;6:6-37.
24. Frishman WH. Chelation therapy for coronary artery disease: panacea or quackery? Am J Med 2001;111:729-30.
25. Kindness G, Frackelton JP. Effect of ethylendiaminetetraacetic acid (EDTA) on platelet aggregation in human blood. J Adv Med 1989;2:519-29.
26. Koen A, McCann D, Boyle A. Some in vivo effects of chelation. II. Animal experimentation. J Chronic Dis 1963;16:329-33.
27. McCann D, Koen A, Zdybek G. Effect of chelation on phosphorus metabolism and experimental atherosderosis. Circ Res 1962;9:880-4.
28. Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses 1988;27:41-9.
29. Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc 1990;82:173-7.
30. Deucher DP. EDTA chelation: an antioxidant strategy. J Adv Med 1988;1:182-90.
31. Duffy SJ, Biegelsen ES, Holbrook M, et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 2001;103:2799-804.
32. Nitenberg A, Payacha F, Ledoux S, Sachs R, Attali J-R, Valensi P. Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation 1998;97:736-43.
33. Green DJ, O'Driscoll JG, Maiorana A, Scrimgeour NB, Weerasooriya R, Taylor RR. Effect of chelation with EDTA and vitamin B therapy on nitric oxide-related endothelial vasodilator funstion. Clin Exp Pharmacol Physiol 1999;26:853-6.
34. Marx JJM, Vreugdenhil MD, Voest EE. Iron chelating agents are not useful in treating atherosclerosis (letter). Ann Intern Med 1994;121.
35. McCord JM, Day ED Jr. Superoxide-dependent production of hydroxyl radical catalyzed by iron-EDTA complex. FEBS Lett 1978;86:139-42.
36. Carr AC, Zhu BZ, Frei B. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). Circ Res 2000;87:349-54.
37. Chen K, Suh J, Carr AC. Vitamin C suppresses oxidative lipid damage in vivo, even in the presence of iron overload. Am J Physiol Endocrinol Metab 2000;279:E1406-12.
38. Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Wermer ER. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 2001;276:40-7.
39. Tiefenbacher CP. Tetrahydrobiopterin: a critical cofactor for eNOS and a strategy in the treatment of endothelial dysfunction. Am J Physiol 2001;280:H2484-8.
40. Gokce N, Keaney JFJ, Frei B, et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1999;99:3234-40.
41. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;93:1107-13.
42. Raitakari O, Adams MR, McCredie R, Griffiths KA, Stocker R, Celermajer DS. Oral vitamin C and endothelial function in smokers: short-term improvement but no sustained beneficial effect. J Am Coll Cardiol 2000;35:1616-21.
43. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
44. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61-9.
45. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999;99:2027-33.
46. Wassmann S, Laufs U, Baumer AT. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GT phase. Mol Pharmacol 2001;59:646-54.
47. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:488-93.
48. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND study. Circulation 1996;94:258-65.
49. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet;1995;19;346;467-71.
50. Treasure CB, Klein L, Weintraub WS, et al. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.